General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Post-transplant Cytomegalovirus (CMV) Infection/disease
Last updated May 10, 2024
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Metastatic castration-resistant prostate cancer (mCRPC) in adult patients (in combination with abiraterone and prednisone or prednisolone)
Last updated May 8, 2024
Paxlovid (nirmatrelvir/ritonavir)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Mild-to-moderate COVID-19, treatment
Last updated May 6, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Crohn's disease
Last updated April 26, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Ulcerative Colitis
Last updated April 26, 2024
Vyalev (foslevodopa foscarbidopa)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
Last updated April 26, 2024
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Ankylosing spondylitis
Last updated April 26, 2024
Status:
Concluded with an LOI
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Primary Hyperoxaluria Type 1
Last updated April 26, 2024
Suboxone (film) (buprenorphine and naloxone)
Status:
Concluded with an LOI
Manufacturer:
Indivior UK Limited
Indication:
Opioid Dependence
Last updated April 23, 2024
Status:
Negotiations were not pursued
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis
Last updated April 23, 2024